ZIGExN acquires AnyCareer for $19.8Mn to expand healthcare recruitment

TOKYO, JAPAN — ZIGExN, a Japanese technology conglomerate specializing in recruitment and HR services, has announced the full acquisition of AnyCareer, a job placement firm based in Tokyo.
The transaction, valued at ¥2.92 billion (US$19.8 million), is set to be finalized on September 1.
AnyCareer offers specialized job matching, with a primary focus on dispensing pharmacies within Japan’s medical sector. With a client portfolio comprising approximately 7,000 companies in the pharmaceutical industry, the firm has established itself as a trusted partner in healthcare recruitment.
Strategic alignment and planned synergies
The acquisition is being made through ZIGExN’s subsidiary, Rejob, which runs its own recruitment platform in the beauty and healthcare domains. The move aims to capitalize on AnyCareer’s deep sector network and client expertise.
【プレスリリース】
株式会社じげんは、当社連結子会社の株式会社リジョブがエニーキャリア株式会社の全株式を取得し、子会社化することについて本日決定いたしましたので、お知らせいたします。https://t.co/CAGRvr57De— じげん【公式】 (@zigexn) July 25, 2025
By merging their offerings, ZIGExN and AnyCareer aim to deliver enhanced value to clients across the healthcare and beauty industries. The deal reflects a broader industry trend of consolidating recruitment expertise to address evolving staffing needs in specialized sectors.
Financial highlights: Revenues and future growth prospects
ZIGExN offers a range of specialized HR and recruitment services, with a presence in several markets, including Japan. The company reported annual revenue of ¥25.45 billion (US$17 million) for its most recent fiscal year. Its current workforce and global footprint underscore its growing influence in niche HR segments.
AnyCareer, meanwhile, reported ¥1.13 billion (US$7.7 million) in revenue and ¥325 million (US$2.2 million) in operating income for the fiscal year ended March 31, 2025. Its workforce, focused on high-touch consulting for pharmacy placements, is expected to grow as ZIGExN invests in organic user acquisition and service expansion.